@article{Icacan_Onalan_Yucesoy_2021, title={Comparison of stent and indomethacin suppository efficacy in the prevention of acute pancreatitis after ERCP}, volume={92}, url={https://mattioli1885journals.com/index.php/actabiomedica/article/view/10962}, DOI={10.23750/abm.v92i4.10962}, abstractNote={<p><strong>Objective:</strong> We aimed to compare stent and indomethacin suppository efficacy in the prevention of acute pancreatitis after ERCP.</p> <p><strong>Materials and Methods:</strong> 76 high-risk patients undergoing ERCP were included in the study. The patients were divided into three groups as indomethacin group, stent group and control group. Indomethacin group (n = 32) received 100 mg rectal indomethacin immediately after ERCP. A 5F pancreatic stent was applied to the stent group (n = 16) during ERCP. No prophylaxis was given to the control group (n = 28).</p> <p><strong>Results:</strong> There was no difference between the groups in terms of age and gender. ERCP pancreatitis was seen in 9.2% (7/76) of the patients. The incidence of ERCP-induced pancreatitis (PEP) was 3.1% (1/32) in the indomethacin group and 21.4% (6/28) in the control group. PEP was not seen in the stent group (0/16). The incidence of PEP was significantly lower in the indomethacin group than in the control group (p = 0.043). However, no significant difference was found between the stent and control groups, stent and indomethacin groups in terms of PEP frequency (p = 0.072, p: 0.90 respectively).</p> <p><strong>Conclusion:</strong> According to the results of our study, rectal indomethacin administration decreased the frequency of PEP in high-risk patients. However, there was no significant difference in PEP prophylaxis between the stent and indomethacin groups.</p>}, number={4}, journal={Acta Biomedica Atenei Parmensis}, author={Icacan, Gamze and Onalan, Erhan and Yucesoy, Mehmet}, year={2021}, month={Sep.}, pages={e2021178} }